Search results for "Immunologic disease"

showing 10 items of 306 documents

Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis

2021

Motor skills are frequently impaired in multiple sclerosis (MS) patients following grey and white matter damage with cortical excitability abnormalities. We applied advanced diffusion imaging with 3T magnetic resonance tomography for neurite orientation dispersion and density imaging (NODDI), as well as diffusion tensor imaging (DTI) in 50 MS patients and 49 age-matched healthy controls to quantify microstructural integrity of the motor system. To assess excitability, we determined resting motor thresholds using non-invasive transcranial magnetic stimulation. As measures of cognitive-motor performance, we conducted neuropsychological assessments including the Nine-Hole Peg Test, Trail Makin…

Malemedicine.medical_treatmentNeuropsychological Testsmultiple sclerosisDisability EvaluationImmunology and AllergyGray MatterMotor skillOriginal ResearchNODDIMotor CortexMiddle AgedTranscranial Magnetic StimulationWhite Mattermedicine.anatomical_structureDiffusion Tensor Imagingtract-based spatial statisticsCardiologyFemalePrimary motor cortexneurite orientation dispersion and density imagingMotor cortexAdultmedicine.medical_specialtymotor thresholdModels NeurologicalImmunologyNeuroimagingGrey matterWhite matterMultiple Sclerosis Relapsing-RemittingInternal medicineMotor systemFractional anisotropyexcitabilitymedicineNeuritesHumansbusiness.industryElectromyographyMultiple sclerosisRC581-607medicine.diseaseEvoked Potentials MotorTranscranial magnetic stimulationImmunologic diseases. AllergybusinessNeurosciencePsychomotor PerformanceDiffusion MRIFrontiers in Immunology
researchProduct

A New Nuclear Function of the Entamoeba histolytica Glycolytic Enzyme Enolase: The Metabolic Regulation of Cytosine-5 Methyltransferase 2 (Dnmt2) Act…

2009

Cytosine-5 methyltransferases of the Dnmt2 family function as DNA and tRNA methyltransferases. Insight into the role and biological significance of Dnmt2 is greatly hampered by a lack of knowledge about its protein interactions. In this report, we address the subject of protein interaction by identifying enolase through a yeast two-hybrid screen as a Dnmt2-binding protein. Enolase, which is known to catalyze the conversion of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP), was shown to have both a cytoplasmatic and a nuclear localization in the parasite Entamoeba histolytica. We discovered that enolase acts as a Dnmt2 inhibitor. This unexpected inhibitory activity was antagonized by…

MethyltransferaseQH301-705.5ImmunologyEnolaseProtozoan ProteinsPolymerase Chain ReactionMicrobiologyEntamoeba histolyticaTwo-Hybrid System TechniquesGenetics and Genomics/EpigeneticsVirologyGeneticsImmunoprecipitationDNA (Cytosine-5-)-MethyltransferasesMicrobiology/ParasitologyBiology (General)Molecular BiologyMolecular Biology/DNA MethylationCell Nucleuschemistry.chemical_classificationbiologyEntamoeba histolyticaInfectious Diseases/Protozoal InfectionsMethylationRC581-607biology.organism_classificationTRNA MethyltransferasesEnolase 2EnzymechemistryBiochemistryPhosphopyruvate HydrataseSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationParasitologyImmunologic diseases. AllergyNuclear localization sequenceResearch ArticlePLoS Pathogens
researchProduct

Increase in gut microbiota after immune suppression in baculovirus-infected larvae.

2013

Spodoptera exigua microarray was used to determine genes differentially expressed in S. exigua cells challenged with the species-specific baculovirus SeMNPV as well as with a generalist baculovirus, AcMNPV. Microarray results revealed that, in contrast to the host transcriptional shut-off that is expected during baculovirus infection, S. exigua cells showed a balanced number of up- and down-regulated genes during the first 36 hours following the infection. Many immune-related genes, including pattern recognition proteins, genes involved in signalling and immune pathways as well as immune effectors and genes coding for proteins involved in the melanization cascade were found to be down-regul…

MicroarraysApplied MicrobiologyvirusesGut floraTranscriptomesBiology (General)Immune ResponseEffectorViral Immune EvasionMicrobiotaAgricultureGenomicsFunctional GenomicsHost-Pathogen InteractionIntestinesLarvaResearch ArticleQH301-705.5Mechanisms of Resistance and SusceptibilityImmunologyVirulenceBiologySpodopteraSpodopteraImmune SuppressionMicrobiologydigestive systemVirusMicrobiologyMolecular GeneticsImmune systemIntegrated ControlGenome Analysis ToolsVirologyMicrobial ControlExiguaGeneticsImmune ToleranceAnimalsGene RegulationMolecular BiologyGeneBiologyImmunity to InfectionsMicrobial PathogensImmunityComputational BiologyImmune DefenseRC581-607biology.organism_classificationNucleopolyhedrovirusesParasitologyPest ControlImmunologic diseases. AllergyGenome Expression AnalysisPLoS Pathogens
researchProduct

Variation in RNA virus mutation rates across host cells.

2014

It is well established that RNA viruses exhibit higher rates of spontaneous mutation than DNA viruses and microorganisms. However, their mutation rates vary amply, from 10−6 to 10−4 substitutions per nucleotide per round of copying (s/n/r) and the causes of this variability remain poorly understood. In addition to differences in intrinsic fidelity or error correction capability, viral mutation rates may be dependent on host factors. Here, we assessed the effect of the cellular environment on the rate of spontaneous mutation of the vesicular stomatitis virus (VSV), which has a broad host range and cell tropism. Luria-Delbrück fluctuation tests and sequencing showed that VSV mutated similarly…

Mutation ratevirusesVirus Replicationmedicine.disease_causeMice[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCricetinaeBaby hamster kidney celllcsh:QH301-705.50303 health sciencesMutation[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases030302 biochemistry & molecular biology3. Good healthViral evolution[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyResearch Articlelcsh:Immunologic diseases. Allergy[SDE.MCG]Environmental Sciences/Global ChangesImmunologyBiologyMicrobiologyEvolution Molecular03 medical and health sciences[SDV.EE.ECO]Life Sciences [q-bio]/Ecology environment/EcosystemsCell Line TumorVirologyGeneticsmedicineAnimalsBiologyMolecular BiologyTropism030304 developmental biology[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthEvolutionary BiologyPoint mutationRNA virusVesiculovirusbiology.organism_classificationVirologyMolecular biology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyViral replicationlcsh:Biology (General)MutationMicrobial EvolutionParasitology[SDE.BE]Environmental Sciences/Biodiversity and Ecologylcsh:RC581-607Population GeneticsPLoS Pathogens
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

TLR4 abrogates the Th1 immune response through IRF1 and IFN-β to prevent immunopathology during L. infantum infection

2020

A striking feature of human visceral leishmaniasis (VL) is chronic inflammation in the spleen and liver, and VL patients present increased production levels of multiple inflammatory mediators, which contribute to tissue damage and disease severity. Here, we combined an experimental model with the transcriptional profile of human VL to demonstrate that the TLR4-IFN-β pathway regulates the chronic inflammatory process and is associated with the asymptomatic form of the disease. Tlr4-deficient mice harbored fewer parasites in their spleen and liver than wild-type mice. TLR4 deficiency enhanced the Th1 immune response against the parasite, which was correlated with an increased activation of de…

PhysiologyGene ExpressionWhite Blood CellsMiceCell SignalingAnimal CellsImmune PhysiologyZoonosesImmunopathologyMedicine and Health SciencesMembrane Receptor SignalingBiology (General)Immune ResponseLeishmaniasisProtozoansLeishmaniaMice Knockout0303 health sciencesbiologyT Cells030302 biochemistry & molecular biologyEukaryotaImmune Receptor SignalingInfectious Diseasesmedicine.anatomical_structureLeishmaniasis VisceralCellular Typesmedicine.symptomLeishmania infantumResearch ArticleSignal TransductionNeglected Tropical DiseasesQH301-705.5Leishmania InfantumImmune CellsImmunologySpleenInflammationLEISHMANIOSE VISCERALMicrobiology03 medical and health sciencesImmune systemVirologyParasitic DiseasesGeneticsmedicineAnimalsMolecular Biology030304 developmental biologyInflammationProtozoan InfectionsBlood CellsOrganismsBiology and Life SciencesCell BiologyInterferon-betaTh1 CellsRC581-607Tropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansToll-Like Receptor 4IRF1Visceral leishmaniasisImmunologyTLR4ParasitologyImmunologic diseases. AllergySpleenInterferon Regulatory Factor-1
researchProduct

Paratransgenic manipulation of a tsetse microRNA alters the physiological homeostasis of the fly’s midgut environment

2021

Tsetse flies are vectors of parasitic African trypanosomes, the etiological agents of human and animal African trypanosomoses. Current disease control methods include fly-repelling pesticides, fly trapping, and chemotherapeutic treatment of infected people and animals. Inhibiting tsetse’s ability to transmit trypanosomes by strengthening the fly’s natural barriers can serve as an alternative approach to reduce disease. The peritrophic matrix (PM) is a chitinous and proteinaceous barrier that lines the insect midgut and serves as a protective barrier that inhibits infection with pathogens. African trypanosomes must cross tsetse’s PM in order to establish an infection in the fly, and PM struc…

PhysiologyGenes InsectBiochemistryAnimals Genetically ModifiedMedical ConditionsGene expressionMedicine and Health SciencesHomeostasisPeritrophic matrixBiology (General)Protozoans0303 health sciencesbiologyGene OntologiesSodalis glossinidiusEukaryotaCardiaGenomicsBody FluidsCell biologyIntestinesNucleic acidsBloodDigestionAnatomyResearch ArticleSymbiotic bacteriaTrypanosomaTsetse FliesQH301-705.5ImmunologyParatransgenesisMicrobiology03 medical and health sciencesVirologyParasitic DiseasesGeneticsAnimalsNon-coding RNAMolecular Biology030304 developmental biologyNatural antisense transcripts030306 microbiologyfungiOrganismsBiology and Life SciencesComputational BiologyTsetse flyMidgutRC581-607Genome Analysisbiology.organism_classificationParasitic ProtozoansGastrointestinal MicrobiomeInsect VectorsGene regulationGastrointestinal TractMicroRNAsTrypanosomiasis AfricanTrypanosomaRNAParasitologyGene expressionImmunologic diseases. AllergyPhysiological ProcessesDigestive SystemPLOS Pathogens
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct

Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-aller…

2021

Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunol…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyVital capacityallergic and non allergic phenotypesAsthma exacerbationSettore MED/10 - Malattie Dell'Apparato Respiratoriobenralizumab.FEV1/FVC ratiochemistry.chemical_compoundPrednisoneInternal medicineIL-5 receptorJournal of Asthma and AllergyImmunology and AllergyMedicineClinical significanceAsthmaOriginal ResearchAllergic and non-allergic phenotypebusiness.industrySevere eosinophilic asthmaTherapeutic effectBenralizumabmedicine.diseaseBenralizumabchemistryasthma exacerbationsExhaled nitric oxideallergic and non-allergic phenotypesbusinesslcsh:RC581-607Allergic and non-allergic phenotypesAsthma exacerbations Benralizumab IL-5 receptor Severe eosinophilic asthmaAllergic and non-allergic phenotypes; Asthma exacerbations; Benralizumab; IL-5 receptor; Severe eosinophilic asthmamedicine.drug
researchProduct